Br J Cancer
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.   
ABSTRACT
To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naïve, small-cell lung cancer (SCLC), good performance status (PS: 0-2), age

Related Questions